Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Am J Transplant. 2011 Dec 7;12(2):438–446. doi: 10.1111/j.1600-6143.2011.03857.x

Table 2.

Comparison of graft survival in patients with high- or low-cumulative exposures to seven BALF biomarkers in the first-year posttransplant. BALF IL-13 levels were not detectable in our patient samples; survival could not be defined for IL-13 exposure

Biomarker Biomarker median pg/mL (25th and 75th percentile) % Graft survival AUC > Median % Graft survival AUC < Median HR for AUC > Median (confidence interval) p-Value
CXCL9 1255 (53, 8739) 50% 100% 9.37 (2.69-32.7) 0.0007
CXCL10 12 847 (4159, 27 191) 55% 95% 5.52 (1.59-19.1) 0.007
MCP-1 18 588 (8920, 101 081) 65% 85% 2.82 (0.81-9.8) 0.096
RANTES 5947 (2500, 9425) 65% 85% 2.56 (0.74-8.94) 0.14
IL1-RA 57 869 (16 813, 108 125) 70% 80% 1.46 (0.42-5.06) 0.56
IL-17 4600 (170, 9304) 80% 70% 0.53 (0.15-1.86) 0.27
IL-13 Undetected Undetected Undetected